OTCM
PKTX
Market cap41kUSD
Oct 08, Last price
0.00USD
1Q
-98.36%
Jan 2017
-99.81%
IPO
-99.99%
Name
ProtoKinetix Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
6.75%
Rev. gr., 5y
%
Revenues
0
Net income
0
P
CFO
-135k
L-39.31%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ProtoKinetix, Incorporated is a biotechnology firm engaged in research and development, specializing in the scientific and medical investigation of glycoproteins known as anti-freeze glycoproteins (AFGPs) and anti-aging glycoproteins (AAGPs). These AFGPs are particularly relevant for their commercial potential within the healthcare sector, with a key area of their development involving utilizing AAGPs for the treatment of dry-eye conditions. Their research efforts are bolstered by a collaborative agreement with the University of British Columbia. Originally incorporated in 1999 as RJV Network, Inc., the company adopted its current name, ProtoKinetix, Incorporated, in July 2003. Its operational headquarters are situated in Marietta, Ohio.
Key people
Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Treasurer, Company Secretary · since 2025
Edward McDonough
Independent Director · since 2015
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||